DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 16, 2006; DOI: 10.1124/dmd.106.009936


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.009936v1
34/9/1530    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, C.
Right arrow Articles by Riddick, D. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, C.
Right arrow Articles by Riddick, D. S


Received for publication February 22, 2006.
Revised May 18, 2006.
Accepted for publication June 13, 2006.

REGULATION OF CONSTITUTIVE MOUSE HEPATIC CYTOCHROMES P450 AND GROWTH HORMONE SIGNALING COMPONENTS BY 3-METHYLCHOLANTHRENE

Chunja Lee 1, Janine R Hutson 1, Vivien Kok-Fung Tzau 1, David S Riddick 1*

1 University of Toronto

* Address correspondence to: E-mail: david.riddick{at}utoronto.ca

Abstract

3-Methylcholanthrene (MC) activates the aryl hydrocarbon receptor and increases expression of cytochrome P450 (P450) enzymes such as CYP1A1. MC also decreases expression of CYP2C11, the major hepatic P450 in male rats that is regulated by pulsatile growth hormone (GH) secretion via a pathway partially dependent on signal transducer and activator of transcription 5b (STAT5b). If disruption of this GH signaling pathway is important for MC?s ability to suppress CYP2C11 transcription, we hypothesize that MC suppresses other male-specific genes (e.g. mouse Cyp2d9) regulated by pulsatile GH with STAT5b-dependence. We examined the time-course of MC?s effects on hepatic P450s and GH signaling components in male C57BL/6 mice. P450 content, heme content, and NADPH P450 oxidoreductase activity were induced 2.3-, 1.8-, and 1.3-fold, respectively, by MC. MC dramatically induced CYP1A1 mRNA, protein, and catalytic activity. MC caused a 42% decrease in CYP2D9 protein, a 28% decrease in CYP2D9 mRNA, and a 27% decrease in testosterone 16{alpha}-hydroxylation activity. MC caused a pronounced decrease in CYP3A protein; however, there was no apparent change in testosterone 6{beta}-hydroxylation activity and changes in mRNA levels for CYP3A forms were relatively small. Expression of GH receptor and major urinary protein 2, a gene regulated by GH with STAT5b-dependence, was decreased by MC at the mRNA level. These results show that MC suppresses mouse Cyp2d9, a pulsatile GH- and STAT5b-dependent male-specific gene, via a pre-translational mechanism that may involve disrupted GH signaling. Mouse CYP3A protein levels are dramatically decreased by MC via a mechanism that is not yet understood.


Key words: Ah receptor, cytochrome P450, gene regulation, polycyclic aromatic hydrocarbons, toxicology


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
R. M. Sawaya and D. S. Riddick
Cytochrome P450 2C11 5'-Flanking Region and Promoter Mediate in Vivo Suppression by 3-Methylcholanthrene
Drug Metab. Dispos., September 1, 2008; 36(9): 1803 - 1811.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. F. Brown Jr, B. A. Mayes, J. B. Silkworth, and S. B. Hamilton
Polychlorinated Biphenyls Modulated Tumorigenesis in Sprague Dawley Rats: Correlation with Mixed Function Oxidase Activities and Superoxide (O2* ) Formation Potentials and Implied Mode of Action
Toxicol. Sci., August 1, 2007; 98(2): 375 - 394.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.